Overview: Hepatitis E IgM TestIntroduction: The Hepatitis E IgM Test detects IgM antibodies to hepatitis E to diagnose acute infection, causing jaundice or fatigue. Following 2023 AASLD guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, supportive care, and improving outcomes in serology for patients with suspected acute hepatitis E, particularly in endemic regions or during outbreaks.
Other Names: Anti-HEV IgM Assay, Acute Hepatitis E Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: Hepatitis E IgM testing began in the 1990s with HEV research. Immunoassays improved in the 2000s, enhancing acute infection detection.
Purpose: Diagnoses acute hepatitis E, guides supportive care, and monitors anti-HEV IgM in patients with jaundice or fatigue.
Test Parameters: 1. Hepatitis E IgM
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like jaundice, fatigue, or nausea, and list medications or travel history.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document jaundice, fatigue, nausea, or travel to hepatitis E endemic areas. Include current medications and recent infections.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for supportive care.
Procedural Considerations: Uses an immunoassay to detect anti-HEV IgM antibodies. Results are available in 3-5 days, enabling clinical decisions. Performed in laboratories, often in outbreak settings.
Factors Affecting Result Accuracy: Improper sample handling or early infection can affect results. Cross-reactivity with other infections may occur.
Clinical Significance: Positive anti-HEV IgM indicates acute hepatitis E, prompting supportive care and monitoring. Negative results may require repeat testing in early infection.
Specialist Consultation: Consult a hepatologist or infectious disease specialist for result interpretation and management planning.
Additional Supporting Tests: HEV PCR, anti-HEV IgG, or liver function tests to confirm acute hepatitis E.
Test Limitations: False negatives may occur in early infection. Clinical correlation and confirmatory testing are needed.
References: AASLD Hepatitis E Guidelines, 2023; Hepatology, Kamar N, 2022.
